December 2016
-
Alexza Pharmaceuticals has announced that its European partner Ferrer has launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients in Romania. Ferrer has a distribution agreement with Galenica for… Read more . . .
-
Vectura has announced that it will acquire Activaero for a total of €130 million ($181 million). The company cited both Activaero’s nebulizer technology and its pipeline of respiratory drugs as part of the rationale for… Read more . . .
-
The New York Times has reported that Hunein “John” Maassab, who developed the FluMist intranasal live attenuated influenza vaccine (LAIV), died on February 1, 2014 in North Carolina. Dr. Maassab received a doctorate in epidemiology… Read more . . .
-
According to Hi-Tech Pharmacal, sales of its fluticasone propionate nasal spray dropped from $23 million in the 3rd quarter of the 2013 fiscal year to only $10.9 million for the same period in 2014. The… Read more . . .
-
Abstracts should be submitted by August 29, 2014 through either: 1) Online submission (IDDA website is under construction and will be announced upon completion.) 2) Email submission to: iddchina@126.com Abstracts should be no more than… Read more . . .
-
Device manufacturer Gerresheimer has announced that it is adding 60,000 sq ft to its production facility in Peachtree City, GA in order to accommodate increased demand for inhalers and other plastic medical devices. Approximately 40,000… Read more . . .
-
Verona Pharma has announced that it is looking to raise up to £14 million through a placing, subscription, and open offer of more than 630 million new ordinary shares, conditioned on approval of shareholders. A… Read more . . .
-
Some day in the not-too-distant future, a dry powder inhaler once used to deliver insulin may help Parkinson’s patients overcome some of the most debilitating symptoms of the disease. Back in 2008, in the wake… Read more . . .
-
Teva has announced the US launch of Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients. The company licensed Adasuve from its developer, Alexza Pharmaceuticals in May 2013. Alexza’s Staccato… Read more . . .
-
According to Sandoz, South Korea has approved 50 mcg/250 mcg and 50 mcg/500 mcg dosages of the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD. The marketing authorization is the first for… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland